

Redempro (plozasiran)
Effective 07/01/2026

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical Benefit Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A		

Overview

Redempro (plozasiran) is an apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA) indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Coverage Guidelines

If member is new to the plan (as evidenced by coverage effective date of less than or equal to 90 days), submission of medical records documenting that the member is currently receiving treatment with requested drug, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted when all of the following criteria are met:

1. Diagnosis of familial chylomicronemia syndrome (FCS) (type 1 hyperlipoproteinemia)
2. Member is 18 years of age or older
3. One of the following:
 - a. Disease is confirmed by the presence of biallelic pathogenic variants in FCS-causing genes (i.e., LPL, GPIHBP1, APOA5, APOC2, or LMF1) as detected by an FDA-approved test or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA)
 - b. A North American FCS (NAFCS) Score of greater than or equal to 45
 - c. A Moulin score greater than 10
4. Both of the following:
 - a. One of the following:
 - i. Member has tried or will receive treatment with standard of care triglyceride lowering therapy (i.e., prescription omega-3 fatty acid [e.g. Lovaza, icosapent ethyl] and a fibrate [e.g., fenofibrate, gemfibrozil])
 - ii. Member has an intolerance to standard of care triglyceride lowering therapy (i.e., prescription omega-3 fatty acid [e.g. Lovaza, icosapent ethyl] and a fibrate [e.g., fenofibrate, gemfibrozil])
 - b. Baseline fasting triglyceride levels are greater than or equal to 880 mg/dL prior to treatment with requested drug
5. Prescribed by or in consultation with one of the following:
 - a. Cardiologist

- b. Endocrinologist
 - c. Gastroenterologist
 - d. Lipid specialist (lipidologist)
6. Requested medication will be used as adjunct to a low-fat diet
 7. Requested medication will not be used in combination with Tryngolza (olezarsen)

Continuation of Therapy

Requests for reauthorization will be approved when the following criteria are met:

1. Submission of medical records (e.g., chart notes) demonstrating positive clinical response to therapy (e.g., reduction in triglyceride levels from baseline)
2. Requested medication will not be used in combination with Tryngolza (olezarsen)

Limitations

1. Initial approvals will be granted for 6 months
2. Reauthorizations will be granted for 12 months
3. The following quantity limits apply

Drug Name and Dosage	Quantity Limit
Redemplo autoinjector	1 autoinjector per 84 days

References

1. Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. *J Intern Med.* 2020;287(4):340-348. doi: 10.1111/joim.13016. Epub 2020 Jan 8.
2. Ballantyne CM, Vasas S, Azizad M, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. *N Engl J Med.* 2024;391(10):899-912. doi: 10.1056/NEJMoa2404143.
3. Chait A. Multifactorial chylomicronemia syndrome. *Curr Opin Endocrinol Diabetes Obes.* 2024;31(2):78-83. doi: 10.1097/MED.0000000000000846.
4. Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. *J Clin Lipidol.* 2018;12(4):898-907.e2. doi: 10.1016/j.jacl.2018.04.009. Epub 2018 Apr 26.
5. Falko JM. Familial chylomicronemia syndrome: A clinical guide for endocrinologists. *Endocr Pract.* 2018;24(8):756-763. doi: 10.4158/EP-2018-0157.
6. Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. *J Clin Lipidol.* 2019;13(1):100-108. doi: 10.1016/j.jacl.2018.11.008.
7. Gaudet D, Pall D, Watts GF, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia. The SHASTA-2 randomized clinical trial. *JAMA Cardiol.* 2024;9(7):620-630. doi:10.1001/jamacardio.2024.0959.
8. Goldberg RB, Chait A. A Comprehensive update on the chylomicronemia syndrome. *Front Endocrinol.* 2020;11:593931. doi: 10.3389/fendo.2020.593931.
9. Hegele RA, Borén J, Ginsberg HN, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. *Lancet Diabetes Endocrinol.* 2020;8(1):50-67.
10. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. *J Clin Lipidol.* 2024:S1933-2874(24)00251-4. doi: 10.1016/j.jacl.2024.09.008.
11. Javed F, Hegele RA, Garg A. Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association. *J Clin Lipidol.* 2025;19(3):382-403. doi: 10.1016/j.jacl.2025.03.013.



12. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score." *Atherosclerosis*. 2018;275:265-272. doi: 10.1016/j.atherosclerosis.2018.06.814.
13. Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2020;105(12):dgaa674.
14. Redemplo. Package insert. Arrowhead Pharmaceuticals, Inc.; November 2025.
15. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78:960-993. doi: 10.1016/j.jacc.2021.06.011.
16. Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. *N Engl J Med*. 2025; 392(2):127-137. doi: 10.1056/NEJMoa2409368.

Review History

04/15/2026 – Created and reviewed at April P&T. Effective 07/01/2026.

